1. Generics Bulletin
  2. >>Business
  3. >>Deals

Mundipharma Strikes Deal For Prestige's Trastuzumab

 
• By Dave Wallace

Mundipharma has struck a deal with Prestige BioPharma for rights to the Singapore-based firm’s biosimilar trastuzumab in selected European markets.

Trees_Puzzle
Mundipharma Wants To Be ‘Partner Of Choice’ In Europe • Source: Shutterstock

Mundipharma will be able to market Prestige BioPharma’s Tuznue (trastuzumab) biosimilar exclusively in “selected European countries” including Austria, Denmark, Finland, France, Norway, Portugal, Spain, Sweden and Switzerland upon approval, according to the terms of an agreement between the two companies.

Prestige had in late June announced positive results from a Phase III trial of the HD201 trastuzumab biosimilar candidate that it recently filed with the European Medicines Agency. (Also see "Henlius Has First ‘China-Developed’ Biosimilar Accepted For EMA Review" - Generics Bulletin, 25 June, 2019

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.